Notes on the Design of Bioequivalence Study: Sofosbuvir/Ledipasvir

Notes on the design of bioequivalence studies with products invited for submission to the WHO Prequalification Team: medicines (PQTm) are issued to aid manufacturers with the development of their product dossier. Deviations from the approach suggested below may be considered acceptable if justified by sound scientific evidence.


Below, additional specific guidance is provided on the invited immediate release products, containing sofosbuvir and ledipasvir.

Pharmacokinetics of sofosbuvir and ledipasvir

Following oral administration of ledipasvir/sofosbuvir to hepatitis C-infected patients, ledipasvir median peak plasma concentration is observed at 4.0 hours post-dose. Sofosbuvir is absorbed quickly and the median peak plasma concentrations observed ~ 1 hour post-dose.

Ledipasvir AUC is dose-proportional over the dose range of 3 to 100 mg. Sofosbuvir is near dose-proportional over the dose range of 200 mg to 400 mg.

Relative to fasting conditions, the administration of a single dose of ledipasvir/sofosbuvir with a moderate-fat or high-fat meal increases the sofosbuvir AUC0-inf by approximately two-fold, but does not significantly affect the sofosbuvir Cmax. The exposures to ledipasvir and GS-331007, the active metabolite of sofosbuvir, are not altered in the presence of either meal type. The combination of sofosvubir and ledipasvir can be administered without regard to food.

The median terminal half-life of ledipasvir in healthy volunteers following administration of ledipasvir/sofosbuvir in the fasted state is 47 hours. The median terminal half-life of sofosbuvir following administration of ledipasvir/sofosbuvir is 0.5 hours.

Guidance for the design of bioequivalence studies:

Taking into account the pharmacokinetic properties of ledipasvir and sofosbuvir, the following guidance with regard to the study design should be taken into account:

**Dose:** A single oral dose of one tablet of sofosbuvir/ledipasvir 400 mg/90 mg should be feasible. The bioanalytical method should be sufficiently sensitive to detect concentrations that are 5% of Cmax in most profiles of each formulation (test or comparator).

**Fasting/fed:** The bioequivalence study should be conducted in the fasted state as sofosbuvir/ledipasvir is recommended to be taken with or without food.

**Subjects:** Healthy adult subjects should be used. It is not necessary to include patients in the bioequivalence study.
Sample size: Information currently available to PQTm indicates that the intra-subject variability in the fasted state for ledipasvir is approximately 45%, and 35% for sofosbuvir. These data will facilitate the calculation of the sample size for the bioequivalence study.

Washout: Taking into account the elimination half-life of ledipasvir in healthy volunteers (approximately 47 hours), a washout period of 14 days is considered sufficient to prevent carry over.

Blood sampling: The blood sampling should be intense in the first two hours after administration to properly characterize the C_{max} of sofosbuvir, and between 3 and 5 hours after administrations for the C_{max} of ledipasvir. It is not necessary to take blood samples beyond 72 hours.

Analytical considerations: Information currently available to PQTm indicates that it is possible to measure sofosbuvir and ledipasvir in human plasma using LC-MS/MS analytical methodology. The bioanalytical method should be sufficiently sensitive to detect concentrations that are 5% of the C_{max} in most profiles of each formulation (test or comparator).

Parent or metabolite data for assessment of bioequivalence: The parent drug is considered to best reflect the biopharmaceutical quality of the product. The data for the parent compounds should be used to assess bioequivalence.

Statistical considerations: The data for sofosbuvir and ledipasvir should meet the following bioequivalence standards in a single-dose, crossover design study:

- The 90% confidence interval of the relative mean AUC_{T} for sofosbuvir and AUC_{0-72h} for ledipasvir of the test to reference product should be within 80–125%
- The 90% confidence interval of the relative mean C_{max} of the test to reference product should be within 80–125%.

Information currently available to PQTm indicates that the comparator product is a highly variable drug product. Therefore, if the Applicant suspects that the variability of C_{max} is high (CV>30%), the applicant may prefer to employ a replicate design study for at least the comparator product in order to scale the acceptance range of C_{max}. For more information on replicate study designs and average scaled bioequivalence, refer to Section 7.9.3 of Annex 7, TRS 992.